Fogarty Siobhan 4

What Happened

• Siobhan Fogarty, Chief Technology Officer of Tonix Pharmaceuticals (TNXP), was granted two derivative awards on Feb 24, 2026: 39,012 and 39,011 shares (total 78,023). Both awards are reported at $0.00 per share on the Form 4 (derivative/option grants), and the filing shows acquisition code "A" (award/grant). This is a compensation grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-24; Form filed: 2026-02-26 (appears timely).
• Awards: 39,012 and 39,011 derivative shares/options; reported price per share: $0.00.
• Total shares granted: 78,023.
• Shares owned after transaction: not specified in the provided data.
• Footnotes from the filing:
  • F1: "One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months."
  • F2: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.

Context

• These are option/derivative awards that vest over time per the schedule in F1; they represent compensation rather than an immediate buy or sell. Such grants are common for executives and do not necessarily signal the insider's near-term market view. The Form 4 reports the grant value as $0.00 per share; further economic value depends on the award type, exercise price (if any), and company stock performance.